Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 90% Improvement Relative Risk Oxygen therapy 73% Vitamin D for COVID-19  Connolly et al.  Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 114 patients in Ireland (March - May 2020) Lower need for oxygen therapy with higher vitamin D levels (p=0.048) c19early.org Connolly et al., Proceedings of the Nu.., Aug 2021 Favors vitamin D Favors control

An observational study of the association of vitamin D status and other patient characteristics with COVID-19 severity and mortality

Connolly et al., Proceedings of the Nutrition Society, doi:10.1017/S0029665121002482
Aug 2021  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 114 hospitalized COVID-19 patients in Ireland, showing higher risk of mortality and oxygen therapy with vitamin D deficiency, with statistical significance for oxygen therapy.
This is the 89th of 184 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 712 vigintillion).
risk of death, 90.4% lower, OR 0.10, p = 0.06, high D levels (≥30nmol/l) 65, low D levels (<30nmol/l) 49, adjusted per study, inverted to make OR<1 favor high D levels (≥30nmol/l), multivariable, RR approximated with OR.
risk of oxygen therapy, 73.3% lower, OR 0.27, p = 0.048, high D levels (≥30nmol/l) 65, low D levels (<30nmol/l) 49, adjusted per study, inverted to make OR<1 favor high D levels (≥30nmol/l), multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Connolly et al., 17 Aug 2021, retrospective, Ireland, peer-reviewed, 8 authors, study period March 2020 - May 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Proceedings of the Nutrition Society (2021), 80 (OCE3), E125 doi:10.1017/S0029665121002482 Irish Section Conference, 22–24 June 2021, Nutrition, health and ageing — translating science into practice – Part A An observational study of the association of vitamin D status and other patient characteristics with COVID-19 severity and mortality M. Connolly1,2, M. Youssef3, A. O’Shea1,2, A. Al Lawati3, S.I. Shah3, S. Walsh3, D. McCartney1 and J. Faul3,4 1 Proceedings of the Nutrition Society School of Biological and Health Sciences, Technological University Dublin, Ireland, 2 School of Medicine, Trinity College Dublin, Dublin, Ireland, 3 Department of Respiratory Medicine, Connolly Hospital Blanchardstown, Dublin, Ireland and 4 James Connolly Memorial Asthma Research Centre, Royal College of Surgeons in Ireland, Connolly Hospital Blanchardstown, Dublin, Ireland Vitamin D deficiency has been proposed to adversely affect COVID-19 severity and clinical outcome(1–4). The current study aimed to evaluate the association between vitamin D status and COVID-19 severity and clinical outcome after adjustment for other factors thought to affect outcome including age and gender. The study included 114 patients from Connolly Hospital, Blanchardstown, Dublin, all of whom tested positive for COVID-19 between March 2020 and May 2020. The independent variables examined included vitamin D status and age, gender, ethnicity, BMI, smoking status and number of comorbidities. Vitamin D status was classified as ‘deficient’ (serum 25(OH)D <30nmol/L), ‘insufficient’ (serum 25(OH)D of 30–49.9nmol/L) and ‘sufficient’ (serum 25(OH)D ≥50nmol/L). The clinical outcomes assessed were ICU admission, oxygen requirement and mortality. Out of the full cohort (n = 114), 64% were male and 17% were over the age of 70. One fifth (n = 23) of the participants did not survive. The most common comorbidity was hypertension (64%). When categorised according to vitamin D status (n = 94), 49 patients (52%) were deficient, 20 (21%) were insufficient and 25 (27%) had sufficient serum 25(OH)D levels. Low vitamin D status was associated with greater mortality on univariate analysis, with 80% of those who died presenting with 25(OH)D levels <30nmol/L vs. 46% of those who survived (P = 0.048). On multivariate regression analysis, the association between vitamin D deficiency (25(OH)D <30nmol/l) and mortality was attenuated (OR 10.37, 95% CI = 0.942-114.1, p = 0.056), but the association of vitamin D deficiency with increased requirement for oxygen therapy persisted (OR = 3.75, 95% CI = 1.01-13.9, P = 0.048). Males were more likely to require ICU admission (OR = 3.43, 95%CI = 1.01-11.65, P = 0.048) and oxygen therapy (OR = 3.34, 95% CI = 1.04-10.71, P = 0.042) than females. When adjusted for other confounders, patients over the age of 70 years were 21.5 times more likely to die than those under the age of 50 years (OR = 21.5, 95% CI = 2.25-205.4, P = 0.008). In addition to older age (>70 years) and male gender which both predict poorer clinical outcome, low vitamin D status appears to be an independent risk factor for more severe disease and mortality in COVID-19. References 1. Pereira M, Dantas Damascena A, et al. (2020) Crit Rev Food Sci Nutr 1–9 2. Ali N (2020) J Infect Public Health 13(10), 1373–80 3. Faul JL, Kerley CP, Love B, et al. (2020) Ir Med J 113(5), 84 4. Ilie PC, Stefanescu S & Smith L (2020) Aging Clin Exp Res 32(7), 1195–8 https://doi.org/10.1017/S0029665121002482 Published online by..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit